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AbStRAct
Objectives: Since 1990s the number of patients diagnosed with endometrial cancer (EC) has doubled. The standard 
treatment method for treating early endometrial cancer is surgery. Some patients require a subsequent adjuvant therapy. 
In early endometrial cancers its application is limited to the populations with a high risk of recurrence. 
The aim of this study was to assess the effectiveness of early endometrial cancer treatment based on an analysis of 5-year 
follow up of EC patients.
Material and methods: The analysis consisted in a retrospective non-randomized interventional study of patients treated 
for early endometrial cancer (FIGO stage IA, IB, II). Its end point was either local (small pelvis) or distant recurrence of the 
disease. Intervention involved an adjuvant treatment applied in selected patients according to the current guidelines for 
EC treatment. There was no randomization for adjuvant and non-adjuvant EC treatment. The study included a total of 
419 patients treated for EC from 2010 to 2012. 
Results: The analysis revealed that 108 patients (25.8%) were diagnosed with the recurrent disease. Out of 112 patients treated 
for stage IA endometrial cancer 32 (28.6%) experienced recurrence. Out of 216 patients at FIGO Stage IB, recurrence was diag-
nosed in 38 (17.6%). In the group of 91 patients treated for FIGO stage II, EC the recurrence was diagnosed in 38 (41.2%) cases. 
conclusions: Early EC treatment results were unsatisfactory and should be improved. The best outcomes were achieved 
in patients with IA stage of EC who received a radiation therapy.
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INtRODUctION
The endometrial cancer morbidity is on the increase, 
with a peak rate between 55 and 59 years of age. Since 
1990s, the number of patients diagnosed with EC has 
doubled. In 1990 and 2010, 2540 and 5125 new EC cases 
were registered, respectively.  
However, an increase of mortality rate is not as dynamic, 
with 763 and 1042 patient deaths due to EC in 1990 and 
2010, respectively. The difference between mortality and 
morbidity rate is due to early symptoms of the disease that 
enable early diagnosis and treatment [1–3]. 
The standard method for treating early endometrial can-
cer is surgery. Total hysterectomy with bilateral salpingo-oo-
phorectomy, either open or laparoscopic is recommended. 
In selected cases of EC (grade 3), pelvic and aortic lymph 
nodes should be removed. This procedure has a proven 
prognostic but not therapeutic value [4]. According to cur-
rent guidelines, selected patients require subsequent ad-
juvant therapy. The aim of the adjuvant treatment (either 
radiation therapy or chemotherapy + radiation therapy) 
is to diminish the risk of local recurrence and/or distant 
metastases [5]. Recommended management of patients at 
the FIGO stage I is either follow-up or vaginal brachytherapy 
(VBT) alone or combined with external beam radiotherapy 
(EBRT). In our study, the patients at IA G1 were in follow up. 
Those at IA G2 stage were either in follow up or underwent 
vaginal brachytherapy. Qualification for the brachytherapy 
was based on pathological examination focused on specific 
risk factors for recurrence. Patients at IA G3 stage underwent 
complete radiation therapy (brachytherapy and external 
beam radiotherapy). 
Patients at stage II were qualified for complete radiation 
therapy (VBT + EBRT). Selected patients at II G3 stage were 
qualified for complete radiation therapy and chemotherapy 
7Marcin Michalak et al., Adjuvant therapy for early endometrial cancer — who benefits the most from a radiation therapy?
www. journals.viamedica.pl/ginekologia_polska
if defined risk factors were present in the pathological report 
(high risk patients).
As both radiotherapy and chemotherapy cause side 
effects, their application must be reasonable and based 
on firm evidence. Randomized clinical trials PORTEC-1 and 
PORTEC-2 revealed that only high risk patients benefited 
from the adjuvant radiotherapy [6–8]. Recognized high risk 
factors included age (the older the worse), Grade 3 tumors, 
deep myometrial invasion, lymph nodes positive for metas-
tases and lymphovascular space invasion [5, 9–11].
Aim of the study
The aim of this study was the Treatment Effectiveness 
Assessment (TEA) of early endometrial cancer based on the 
analysis of 5-year follow up of EC patients. 
MAtERIAL AND MEtHODS
The analysis was a retrospective interventional non-
randomized study of patients treated for early endometrial 
cancer (FIGO stage IA, IB and II). Its end point was either 
local (small pelvis) or distant recurrence of the disease. 
Intervention included an adjuvant treatment applied in 
selected patients according to the current guidelines for 
EC treatment. There was no randomization for adjuvant 
and non-adjuvant EC treatment. The study included a total 
of 419 patients treated for EC from 2010 to 2012. 
All the patients were thoroughly analyzed for prognostic 
factors of population-based, clinical, and therapeutic nature 
and classified into two groups. The first group included 
the patients diagnosed with the recurrent disease, and the 
second those with no symptoms of the disease (controls). 
Analysis of clinical data (medical history) revealed no 
significant differences between the patients. Detailed 
analysis is presented in Table 1.
All the patients underwent surgical treatment and 
qualification for subsequent adjuvant treatment was based 
on the final pathological examination. The patients received 
external beam radiation therapy (EBRT) with brachytherapy 
(VBT) or brachytherapy alone as a part of adjuvant treatment. 
EBRT was applied with Intense Modulate Radiation Therapy 
(IMRT) method in all cases. The range of physical dose of 
teleradiotherapy to the tumor and lymph node region was 
45–50 Gy. Vaginal applications were given with High Dose 
Rate (HDR) brachytherapy. Dose distribution in applicators 
was 0.5 cm out of the first and half of the second segment 
of the vaginal cylinder. The range of physical dose of VBT 
was 18–37.5 Gy (Tab. 2).
The patients diagnosed with the recurrent disease 
received adequate treatment as per current radiotherapy 
and/or chemotherapy guidelines.  
Time frame of the analysis was limited to the years 
2010 – 2012 due to: a) modification of FIGO staging system 
(introduced in 2009) and b) 5-year follow up (completed 
in 2017). 
Statistical analysis
Differences between the groups were analyzed using 
Statistic 6.0 (StatSoft, USA). t-Student test was used for com-
parison of means (data sets with parametric distribution). 
Mann-Whitney test was used for comparison of medians 
(data sets with non-parametric distribution). The chi- 
squared test with Yates continuity correction was employed 
to determine the significance of differences between 
variable frequencies of the analyzed groups. Assumed level 
of significance was p < 0.05. 
RESULtS
The analysis showed that 108 (25.8%) out of 419 patients 
were diagnosed with the recurrent disease. Among 
112 patients treated for stage IA EC, 32 (28.6%) experienced 
the recurrence. Out of 216 patients at FIGO Stage IB, 
38 (17.6%) were diagnosed with the recurrent disease. In 
the group of 91 patients treated for FIGO stage II EC 38 cases 
(41.2%) of recurrence were diagnosed. Summarized data are 
presented in Table 3. 
Some parameters describing treatment effectiveness 
based on the data outlined in Table 2 were analyzed and 
are discussed below.
Application of the adjutant treatment reduced rela-
tive risk of recurrence in patients at IA G1 stage of EC by 
over eight times (Tab. 4). Meanwhile, 88% of patients who 
received adjuvant treatment avoided recurrence at this 
stage of the disease. The adjuvant treatment reduced the 
relative risk of recurrence in patients at II G1 stage by only 
2.9 times. This means that 66% of patients who received 
the adjuvant treatment avoided recurrence. The adjuvant 
treatment was also effective in patients at IB G2 stage, as 
10 for every 12 patients who received it avoided recurrence. 
In other words, the adjuvant treatment at this stage of the 
disease reduced the relative risk of recurrence by approxi-
mately six times and 83% of the treated patients remained 
disease-free (Tab. 4). 
Furthermore, the analysis of therapeutic methods 
(Tab. 2) showed that the addition of vaginal brachytherapy 
in FIGO IA patients significantly (8.3 times) reduced the risk 
of recurrence. More detailed data is presented in Table 5.
Median progression free survival (PFS) for all the patients 
included in the study was 28 months (2–125 months). 
A more detailed analysis revealed that in the group of 
patients at FIGO stages IA, IB and II the median PFS was 
18 months (2–125), 28 months (3–120), and 32 months 
(2–125), respectively. 
The analysis also included the localization of the 
recurrence. In the group of 108 recurring patients, in 44 cases 
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(41%) the recurrence was localized in small pelvis and in 
64 cases (59%) metastases were detected either in paraaortic 
lymph nodes or in other distant localizations. The patients 
at FIGO stage IA experienced recurrences in small pelvis in 
table 1. Clinical characteristics of Patients included into the study
Stage Recurrent disease control p
FIGO I A
Number of patients 32 79 –
Age [Years] 62 (52–82) 62 (45–82) 0.618*
BMI [kg/m2] 31.2 ± 7.3 32.9 ± 7.4 0.272**
FMP [Years] 14 (10–17) 14 (10–18) 0.165*
Menopause [Years] 49.5 (43–57) 50 (41–50) 0.120*
Labour/Delivery 2 (0–2) 2 (0–6) 0.816*
Still birth 2 (6.25%) 17 (21.5%) 0.098***
Hypertension 21 (65.6%) 49 (62.0%) 0.889***
Diabetes mellitus 9 (28.1%) 15 (18.9%) 0.421***
Coronary artery disease 6 (18.7%) 7 (8.9%) 0.253***
Stroke 1 (3.1%) 3 (3.8%) 0.697***
Hypothyreosis 4 (12.5%) 5 (6.3%) 0.487***
Glaucoma 1 (3.1%) 1 (1.3%) 0.904***
Varicose veins 3 (9.4%) 5 (6.3%) 0.875***
FIGO I b
Number of patients 38 178 –
Age [Years] 66 (54–84) 63 (46–85) 0.822*
BMI [kg/m2] 30.6 ± 6.4 31.9 ± 5.6 0.191**
FMP [Years] 14 (11–17) 14 (10–18) 0.918*
Menopause [Years] 51 (40–56) 51 (35–59) 0.765*
Labour/Delivery 2 (0–9) 2 (0–6) 0.657*
Still birth 5 (13.1%) 39 (21.9%) 0.321***
Hypertension 22 (57.9%) 112 (62.9%) 0.692***
Diabetes mellitus 8 (21.0%) 42 (23.6%) 0.900***
Coronary artery disease 4 (10.5%) 18 (10.1%) 0.826***
Stroke 1 (2.6%) 4 (2.2%) 0.652***
Hypothyreosis 3 (7.9%) 11 (6.2%) 0.979***
Glaucoma 1 (2.6%) 7 (18.4%) 0.930***
Varicose veins 4 (10.5%) 11 (6.2%) 0.545***
FIGO II
Number of patients 38 51 –
Age [Years] 60 (46–81) 63 (40–78) 0.084*
BMI [kg/m2] 32.3 ± 6.9 31.7 ± 6.3 0.771**
FMP [Years] 14 (9–18) 12 (11–20) 0.277**
Menopause [Years] 50 (46–54) 51 (45–58) 0.307**
Labour/Delivery 2 (0–6) 3 (0–5) 0.001**
Still birth 6 (15.8%) 9 (17.6%) 0.956***
Hypertension 16 (42.1%) 26 (50.9%) 0.538***
Diabetes mellitus 5 (13.1%) 11 (21.6%) 0.457***
Coronary artery disease 6 (15.8%) 7 (13.7%) 0.975***
Stroke 1 (2.6%) 1 (1.9%) 0.609***
Hypothyreosis 4 (10.5%) 6 (11.8%) 0.876***
Glaucoma 1 (2.6%) 2 (3.9%) 0.795***
Varicose veins 7 (18.4%) 2 (3.9%) 0.059***
FMP — Firs Menstrual Period; BMI — Body Mass Index; *Mann Whitney Test; **t-Student test; ***χ2 Test with Yates Continuity Correction
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19 cases (59%) and distant metastases in 13 cases (41%). 
Among the patients at IB stage, 11 (29%) recurrences were 
found in small pelvis and distant metastases were diagnosed 
in 27 cases (71%). For the patients at stage II, these values 
were 14 (37%) for small pelvis and 24 (63%) for distant 
metastases. 
Detailed analysis of metastasis localization revealed 
a correlation between the cancer grade and metastasis 
pattern. The more aggressive the cancer was (G1 -> G3), the 
more likely distant metastases were diagnosed. The patients 
with well differentiated tumors (G1) at FIGO stage IA were 
at risk of a local recurrence (vaginal vault), while those with 
poorly differentiated tumors were at risk of distant metas-
tases. In the group of patients at FIGO stages IB and II, the 
recurrence pattern was different. All the patients were at 
risk of distant metastases, and the risk was increasing with 
the cancer grade (Tab. 6). 
Contrary to the group who received the adjuvant treat-
ment, the number of patients who did not receive it was 
relatively small and unequivocal conclusions could not be 
drawn (Tab. 7). 
The analysis of population-based factors such as age, 
BMI, age of the first menstrual period, number of births 
and miscarriages, or presence of concomitant diseases did 
not reveal any significant differences between controls and 
patients diagnosed with EC (Tab. 1).
DIScUSSION
Early endometrial cancer is considered a well differen-
tiated malignant disease with relatively good prognosis 
that reflects low risk of either local recurrences or distant 
metastases. On the other hand, EC is a non-homogenous 
disease that comprises at least two types differing in histol-
ogy, course of the disease, and treatment. Therefore, despite 
good prognosis, endometrial cancer patients still suffer from 
treatment failure and recurrences.
table 2. Characteristics of Patients included into the study — focus on radiation therapy doses
Stage Recurrent disease control p
FIGO I A
Number of patients 32 79 –
Dose of Teletherapy [Gy] 0 (0–45) 0 (0–45) 0.857**
Dose of Brachytherapy [Gy] 0 (0–30) 28 (0–37.5) 0.00006**
FIGO I b
Number of patients 38 178 –
Dose of Teletherapy [Gy] 45 (0–45) 45 (0–50) 0.563**
Dose of Brachytherapy [Gy] 18 (0–35) 18 (0–30) 0.964**
FIGO II
Number of patients 38 51 –
Dose of Teletherapy [Gy] 45 (0–50) 45 (0–50) 0.987**
Dose of Brachytherapy [Gy] 18 (0–20) 18 (18–30) 0.415**
*Mann Whitney Test; **t–Student test; ***χ2 Test with Yates Continuity Correction
table 3. General juxtaposition of the results – recurrence rate of 
early Endometrial Cancer
Stage (FIGO) Recurrence rate
IA 28.6%
IB 17.6%
II 41.2%
table 4. Impact of adjuvant treatment on selected parameters
Stage Grade RR RRR 1/RR PF NNt
I A
G1 0.12 -0.88 8.30 88% -2.22
G2 0.31 -0.69 3.27 69% -2.52
G3 – – – – –
I b
G1 0.24 -0.76 4.25 76% -2.62
G2 0.17 -0.83 5.75 83% -1.21
G3 – – – – –
II
G1 0.34 -0.66 2.90 66% -1.53
G2 – – – – –
G3 – – – – –
RR — Relative Risk; RRR — Relative Risk Reduction; 1/RR — inverse Relative Risk; PF — Preventive Fraction; NNT — Number Needed to Treat
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The analysis of early EC treatment efficiency provided in 
this paper revealed 23% recurrence rate. This is not consist-
ent with the outcome of other authors [12, 13]. The higher 
cancer stage and/or grade were, the higher risk of either 
local recurrence or distant metastases was. 
Our group of patients was not homogeneous in terms of 
clinical stage of disease, grade and applied treatment. The 
patients were initially qualified for the surgical treatment 
and operated on at different centers. This further enhanced 
intergroup diversity. 
The analyzed cohort revealed high recurrence rate in 
the patients at stage IA G1 (Tab. 8). This group of patients 
should have had a good prognosis. Thus, if none risk fac-
tors for recurrence were present, follow-up after surgery 
was a recommended procedure. Adjuvant treatment is 
not recommended, unless any risk factor for recurrence is 
detected in individual cases. In 2009 FIGO staging system 
for endometrial cancer changed. The modification shifted 
patients with former FIGO stage IB (defined as cancer in-
filtration into myometrium no more than halfway through 
uterine wall) to the stage IA. Since the new definition of 
FIGO stage IA had been established, there were two differ-
ent groups of patients, i.e. the patients with EC limited to 
the endometrium (with no cancer invasion through base-
ment membrane) and patients with superficial myometrial 
invasion (less than 50% of the uterine wall). This means that 
the patients previously treated with VBT, are now disquali-
fied from any adjuvant treatment (if other risk factors are 
absent). In our analysis, adjuvant brachytherapy applied 
in this group (FIGO IA G1) significantly reduced the risk 
of EC recurrence (p = 0.0006) (Tab. 2). Similar results were 
provided by other authors [8, 14–17].
Our analysis also revealed high recurrence rate in the 
group of patients at FIGO stage II. This means that patients 
who underwent a complete radical radiation therapy are still 
at high risk of recurrence. This in turn may suggest that the 
disease at the time of therapy planning was more advanced 
than the diagnosis based on histopathological report stated. 
One of the most important topics is quality and accu-
racy of the histopathological report. Boer at al. re-evaluated 
histopathological reports of the patients included into POR-
TEC-3 study in England and Norway [18]. The re-evaluation 
table 5. Relation between median PFS and FIGO stage and cancer 
grade
Stage Grade
Median time to recurrence [months]
Adjuvant treatment No Adjuvant treatment
I A
G1 11 29  (3–125)
G2 14   (2–57) 13  (6–46)
G3 4 –
I b
G1 35  (5–76) –
G2 28  (3–120) 13
G3 25  (9–83) –
II
G1 34  (11–125) 25 (15–34)
G2 30  (2–78) –
G3 29  (3–54) –
table 7. Metastases (localization and rate) in group of early EC 
patients. who did not receive any adjuvant treatment
Stage Grade
Metastases
Lokalization Rate [%]
I A
G1 Local (vaginal vault)Distant
58
42
G2 Local (vaginal vault)Distant
60
40
G3 Local (vaginal vault)Distant
–
–
I b
G1 Local (vaginal vault)Distant
–
–
G2 Local (vaginal vault)Distant
100
0
G3 Local (vaginal vault)Distant
–
–
II
G1 Local (vaginal vault)Distant
100
0
G2 Local (vaginal vault)Distant
–
–
G3 Local (vaginal vault)Distant
–
–
table 6. Metastases (localization and rate) in group of early EC 
patients. who received adequate adjuvant treatment
Stage Grade Metastases Rate %
I A
G1 Local (vaginal vault)Distant
100.0
0.0
G2 Local (vaginal vault)Distant
43.0
47.0
G3 Local (vaginal vault)Distant
0.0
100.0
I b
G1 Local (vaginal vault)Distant
33.3
66.7
G2 Local (vaginal vault)Distant
30.0
70.0
G3 Local (vaginal vault)Distant
12.5
87.5
II
G1 Local (vaginal vault)Distant
33.3
66.7
G2 Local (vaginal vault)Distant
12.0
88.0
G3 Local (vaginal vault)Distant
0.0
100.0
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revealed modification of at least one assessed factor in 43% 
of cases. In 34% of cases the type of malignancy changed, in 
27% the depth of infiltration, and in 19% the cancer grade 
[18]. These modifications considerably altered indications 
for adjuvant treatment, and demonstrated that the patients 
should have been qualified for this type of therapy [19–23]. 
The discussed discrepancies in treatment results might 
be caused by differences in surgical procedures and speci-
men preparation at different centers and pathology de-
partments (differences in laboratory protocols of specimen 
preparation). Those differences affected accuracy of the final 
pathological reports, as described and analyzed by Mitchard 
and Hirschowitz [24, 25]. 
The final parameter to be discussed is positive LVSI. Re-
cent studies implied that positive LVSI at early stages of EC 
is sufficient to recommend a more aggressive treatment, 
especially in cases of coexisting risk factors. Bosse et al. 
re-evaluated histopathological data of the patients included 
into PORTEC-1 and PORTEC-2 study [18]. They found out that 
positive LVSI was an independent negative prognostic factor 
for local recurrence, distant metastases and overall survival 
[26]. They also concluded that histopathological examinations 
should be performed at referential centers [27–33].
For a long time, European scientific organizations 
engaged in EC treatment would not agree on the 
guidelines on EC management. In 2016, European Society 
of Gynecological Oncology (ESGO), European Society for 
Radiotherapy and Oncology (ESTRO) and European Society 
of Medical Oncology (ESMO) finally published a consensus 
outlining diagnostics, qualification for treatment and 
extent of surgery at specific stages of the disease. They 
also provided detailed guidelines for adjuvant treatment 
and post treatment follow up. There is still place for immune 
therapy and targeted therapy in EC that will hopefully have 
positive impact on PFS and OS [34, 35]. 
The next step should be an evaluation of patients treat-
ed for recurrence that were exposed to radiation and/or 
chemotherapy.
cONcLUSIONS
Early EC treatment outcomes were unsatisfactory 
and should be improved. High rate of recurrence in early 
endometrial cancer reported recently encouraged us 
to investigate the factors responsible for the treatment 
failure. In patients at IA G1 stage brachytherapy seems 
justified even though studies suggest only careful follow-
up. Brachytherapy introduced in the analyzed group 
significantly reduced local recurrence.
In patients at this stage, the adjuvant treatment (vaginal 
brachytherapy alone) seemed reasonable. The women who 
underwent this treatment scored better than those who did 
not receive any adjuvant therapy, and we concluded that 
vaginal brachytherapy dramatically improved locoregional 
control of the disease. 
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